204 related articles for article (PubMed ID: 20011514)
1. The acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes.
Blom SM; Schmitt N; Jensen HS
PLoS One; 2009 Dec; 4(12):e8251. PubMed ID: 20011514
[TBL] [Abstract][Full Text] [Related]
2. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
Bentzen BH; Schmitt N; Calloe K; Dalby Brown W; Grunnet M; Olesen SP
Neuropharmacology; 2006 Nov; 51(6):1068-77. PubMed ID: 16904708
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
4. From pan-reactive KV7 channel opener to subtype selective opener/inhibitor by addition of a methyl group.
Blom SM; Rottländer M; Kehler J; Bundgaard C; Schmitt N; Jensen HS
PLoS One; 2014; 9(6):e100209. PubMed ID: 24956197
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
7. Inactivation as a new regulatory mechanism for neuronal Kv7 channels.
Jensen HS; Grunnet M; Olesen SP
Biophys J; 2007 Apr; 92(8):2747-56. PubMed ID: 17237198
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of ICA-27243 on cloned K(V)7 channels.
Blom SM; Schmitt N; Jensen HS
Pharmacology; 2010; 86(3):174-81. PubMed ID: 20714208
[TBL] [Abstract][Full Text] [Related]
9. Retigabine holds KV7 channels open and stabilizes the resting potential.
Corbin-Leftwich A; Mossadeq SM; Ha J; Ruchala I; Le AH; Villalba-Galea CA
J Gen Physiol; 2016 Mar; 147(3):229-41. PubMed ID: 26880756
[TBL] [Abstract][Full Text] [Related]
10. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
11. Combining endocannabinoids with retigabine for enhanced M-channel effect and improved KV7 subtype selectivity.
Larsson JE; Karlsson U; Wu X; Liin SI
J Gen Physiol; 2020 Aug; 152(8):. PubMed ID: 32365171
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.
Xiong Q; Sun H; Zhang Y; Nan F; Li M
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3128-33. PubMed ID: 18272489
[TBL] [Abstract][Full Text] [Related]
13. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.
Yeung S; Schwake M; Pucovský V; Greenwood Ia
Br J Pharmacol; 2008 Sep; 155(1):62-72. PubMed ID: 18536747
[TBL] [Abstract][Full Text] [Related]
14. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
Wu YJ; Boissard CG; Chen J; Fitzpatrick W; Gao Q; Gribkoff VK; Harden DG; He H; Knox RJ; Natale J; Pieschl RL; Starrett JE; Sun LQ; Thompson M; Weaver D; Wu D; Dworetzky SI
Bioorg Med Chem Lett; 2004 Apr; 14(8):1991-5. PubMed ID: 15050644
[TBL] [Abstract][Full Text] [Related]
15. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
16. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds.
Xiong Q; Gao Z; Wang W; Li M
Trends Pharmacol Sci; 2008 Feb; 29(2):99-107. PubMed ID: 18206251
[TBL] [Abstract][Full Text] [Related]
17. Functional implications of KCNE subunit expression for the Kv7.5 (KCNQ5) channel.
Roura-Ferrer M; Etxebarria A; Solé L; Oliveras A; Comes N; Villarroel A; Felipe A
Cell Physiol Biochem; 2009; 24(5-6):325-34. PubMed ID: 19910673
[TBL] [Abstract][Full Text] [Related]
18. Neural KCNQ (Kv7) channels.
Brown DA; Passmore GM
Br J Pharmacol; 2009 Apr; 156(8):1185-95. PubMed ID: 19298256
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Miceli F; Soldovieri MV; Ambrosino P; Manocchio L; Mosca I; Taglialatela M
Curr Med Chem; 2018; 25(23):2637-2660. PubMed ID: 29022505
[TBL] [Abstract][Full Text] [Related]
20. Atomic basis for therapeutic activation of neuronal potassium channels.
Kim RY; Yau MC; Galpin JD; Seebohm G; Ahern CA; Pless SA; Kurata HT
Nat Commun; 2015 Sep; 6():8116. PubMed ID: 26333338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
